Share This Page
Drug Price Trends for DESOGESTREL-EE
✉ Email this page to a colleague
Average Pharmacy Cost for DESOGESTREL-EE
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| DESOGESTREL-EE 0.15-0.03 MG TB | 51862-0514-01 | 0.16885 | EACH | 2024-07-17 |
| DESOGESTREL-EE 0.15-0.03 MG TB | 51862-0514-01 | 0.14468 | EACH | 2024-06-19 |
| DESOGESTREL-EE 0.15-0.03 MG TB | 51862-0514-01 | 0.11187 | EACH | 2024-05-22 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Market Analysis and Price Projections for Desogestrel-Ethinyl Estradiol
Introduction
Desogestrel, combined with ethinyl estradiol, is a widely used contraceptive medication, known for its effectiveness in preventing pregnancy and managing various gynecological conditions. This article delves into the market analysis and price projections for desogestrel-ethinyl estradiol, providing insights into its market dynamics, pricing, and future outlook.
Market Overview
Desogestrel-ethinyl estradiol is part of the broader contraceptive market, which is driven by increasing demand for effective and convenient birth control methods. The global desogestrel market is expected to grow significantly over the forecast period, driven by factors such as rising awareness about reproductive health, increasing female workforce participation, and advancements in contraceptive technologies[1].
Regional Analysis
The desogestrel market is segmented across various regions, with different regions exhibiting distinct growth patterns. The North American and European markets are expected to dominate the global desogestrel market due to high awareness and acceptance of hormonal contraceptives. However, emerging markets in Asia-Pacific and Latin America are also showing promising growth due to increasing healthcare expenditure and government initiatives to improve reproductive health[1].
Market Size and Revenue
The global desogestrel market is projected to experience a steady growth rate during the forecast period from 2025 to 2031. The market size is expected to increase, driven by the rising demand for combined oral contraceptives (COCs) and the expanding product portfolio of pharmaceutical companies. The compound annual growth rate (CAGR) for desogestrel tablets is anticipated to be significant, reflecting the growing need for effective contraceptive solutions[1].
Pricing and Cost Analysis
The pricing of desogestrel-ethinyl estradiol varies based on the formulation, dosage, and region. In the United States, the cost for a biphasic oral tablet of desogestrel-ethinyl estradiol can range from $36.38 to $56.47 for a supply of 84 tablets, depending on the pharmacy and any available discounts or coupons[2].
Brand Names and Generic Versions
Desogestrel-ethinyl estradiol is available under several brand names, including Apri, Viorele, Enskyce, and Kariva. Generic versions of these medications are also available, which can be more cost-effective for consumers. For instance, the generic version of desogestrel-ethinyl estradiol can be purchased at a lower price point compared to branded versions[2].
Patient Assistance and Copay Programs
While there are no specific patient assistance programs (PAPs) available for desogestrel-ethinyl estradiol, patients can benefit from discount cards and copay programs. These programs can significantly reduce the cost of the medication, making it more accessible to a wider audience[2].
Pharmacokinetics and Efficacy
Desogestrel is a third-generation progestogen that is rapidly metabolized into etonogestrel, its active metabolite. When combined with ethinyl estradiol, it forms an effective contraceptive regimen. The pharmacokinetics of desogestrel and etonogestrel have been extensively studied, highlighting their suitability for both oral and parenteral contraceptive formulations[4].
Market Trends and Drivers
Several trends and drivers are influencing the desogestrel market:
- Increasing Awareness and Acceptance: Growing awareness about reproductive health and the importance of birth control is driving the demand for desogestrel-ethinyl estradiol.
- Advancements in Contraceptive Technologies: Continuous innovations in contraceptive methods, such as the development of more convenient and effective formulations, are attracting more users.
- Government Initiatives: Public health initiatives aimed at improving reproductive health and reducing unintended pregnancies are boosting the market[1].
Market Restraints and Challenges
Despite the positive trends, the market faces several restraints and challenges:
- Side Effects and Health Risks: Desogestrel-ethinyl estradiol, like other hormonal contraceptives, carries risks such as venous thromboembolism (VTE) and arterial thromboembolism (ATE), which can deter some users[3].
- Regulatory Hurdles: Strict regulatory requirements and post-marketing surveillance can impact the market growth.
- Competition from Alternative Contraceptives: The availability of other contraceptive methods, such as intrauterine devices (IUDs) and subdermal implants, can compete with desogestrel-ethinyl estradiol for market share[1].
Price Projections
The prices of desogestrel-ethinyl estradiol are expected to remain relatively stable, with minor fluctuations based on market conditions and competition. However, the overall cost-effectiveness of generic versions and the availability of discount programs are likely to keep the prices accessible for a broad range of consumers.
Future Outlook
The future outlook for the desogestrel-ethinyl estradiol market is positive, driven by increasing demand and advancements in contraceptive technologies. As more women seek effective and convenient birth control methods, the market is expected to continue growing. However, pharmaceutical companies must navigate regulatory challenges and address concerns about side effects to maintain market traction.
Key Takeaways
- Growing Market Demand: The global desogestrel market is expected to grow significantly due to increasing awareness and demand for effective birth control methods.
- Regional Variations: North America and Europe are expected to dominate the market, while emerging markets show promising growth.
- Pricing and Cost: Prices vary based on formulation and region, with generic versions offering cost-effective alternatives.
- Pharmacokinetics and Efficacy: Desogestrel-ethinyl estradiol is highly effective, with desogestrel rapidly metabolizing into its active metabolite etonogestrel.
- Market Trends and Drivers: Increasing awareness, advancements in technology, and government initiatives are key drivers of the market.
FAQs
Q: What are the common brand names for desogestrel-ethinyl estradiol? A: Common brand names include Apri, Viorele, Enskyce, and Kariva.
Q: How much does desogestrel-ethinyl estradiol typically cost? A: The cost can range from $36.38 to $56.47 for a supply of 84 tablets, depending on the pharmacy and any available discounts.
Q: What are the potential side effects of desogestrel-ethinyl estradiol? A: Potential side effects include venous thromboembolism (VTE) and arterial thromboembolism (ATE), among others.
Q: Are there any patient assistance programs available for desogestrel-ethinyl estradiol? A: There are no specific patient assistance programs, but discount cards and copay programs can help reduce costs.
Q: What is the active metabolite of desogestrel? A: The active metabolite of desogestrel is etonogestrel.
Sources
- Cognitivemarketresearch.com: Desogestrel Market Report 2024 (Global Edition)
- Drugs.com: Desogestrel/ethinyl estradiol Prices, Coupons, Copay Cards & Patient Assistance
- Accessdata.fda.gov: Post marketing study to quantify fatal and nonfatal VTE/ATE risk in women
- Pubmed.ncbi.nlm.nih.gov: Pharmacokinetic evaluation of desogestrel as a female contraceptive
- Mypharmacy.co.uk: Desogestrel 75mcg Mini-Pill (84 Tablets)
More… ↓
